Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB-mediated pathogenic pathways. by Swarup, Vivek et al.
UC Irvine
UC Irvine Previously Published Works
Title
Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB-mediated 
pathogenic pathways.
Permalink
https://escholarship.org/uc/item/9w0495dt
Journal
The Journal of experimental medicine, 208(12)
ISSN
0022-1007
Authors
Swarup, Vivek
Phaneuf, Daniel
Dupré, Nicolas
et al.
Publication Date
2011-11-14
DOI
10.1084/jem.20111313
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Article
The Rockefeller University Press $30.00
J. Exp. Med. Vol. 208 No. 12 2429-2447
www.jem.org/cgi/doi/10.1084/jem.20111313
2429
Amyotrophic lateral sclerosis (ALS) is an adult-
onset neurodegenerative disorder characterized 
by the progressive degeneration of motor neu-
rons in the brain and spinal cord. Approximately 
10% of ALS cases are familial and 90% are spo-
radic. Recently, TDP-43 (TAR DNA-binding 
protein 43) has been implicated in ALS 
(Neumann et al., 2006). TDP-43 is a DNA/
RNA-binding 43-kD protein that contains an 
N-terminal domain, two RNA recognition 
motifs and a glycine-rich C-terminal domain, 
characteristic of the heterogeneous nuclear 
RNP class of proteins (Dreyfuss et al., 1993). 
TDP-43, normally observed in the nucleus, is 
detected in pathological inclusions in the cyto-
plasm and nucleus of both neurons and glial 
cells of ALS and frontotemporal lobar degener-
ation with ubiquitin inclusions (FTLD-U) 
cases (Arai et al., 2006; Neumann et al., 2006). 
The inclusions consist prominently of TDP-43 
C-terminal fragments of 25 kD. The involve-
ment of TDP-43 with ALS cases led to the dis-
covery of TDP-43 mutations found in ALS 
patients. Dominant mutations in TARDBP, 
which codes for TDP-43, were reported by sev-
eral groups as a primary cause of ALS (Gitcho 
et al., 2008; Kabashi et al., 2008; Sreedharan et al., 
2008; Van Deerlin et al., 2008; Corrado et al., 
2009; Daoud et al., 2009) and may account 
for 3% of familial ALS cases and 1.5% of 
sporadic cases.
Neuronal overexpression at high levels of 
WT or mutant TDP-43 in transgenic mice 
caused a dose-dependent degeneration of cor-
tical and spinal motor neurons but with no 
cytoplasmic TDP-43 aggregates (Wegorzewska 
et al., 2009; Stallings et al., 2010; Wils et al., 
2010; Xu et al., 2010), raising up the possibility 
that an up-regulation of TDP-43 in the nucleus 
rather than TDP-43 cytoplasmic aggregates may 
contribute to neurodegeneration. The physio-
logical role of TDP-43 and the pathogenic 
pathways of TDP-43 abnormalities are not well 
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TDP-43 (TAR DNA-binding protein 43) inclusions are a hallmark of amyotrophic lateral 
sclerosis (ALS). In this study, we report that TDP-43 and nuclear factor B (NF-B) p65 
messenger RNA and protein expression is higher in spinal cords in ALS patients than 
healthy individuals. TDP-43 interacts with and colocalizes with p65 in glial and neuronal 
cells from ALS patients and mice expressing wild-type and mutant TDP-43 transgenes but 
not in cells from healthy individuals or nontransgenic mice. TDP-43 acted as a co-activator 
of p65, and glial cells expressing higher amounts of TDP-43 produced more proinflamma-
tory cytokines and neurotoxic mediators after stimulation with lipopolysaccharide or reac-
tive oxygen species. TDP-43 overexpression in neurons also increased their vulnerability to 
toxic mediators. Treatment of TDP-43 mice with Withaferin A, an inhibitor of NF-B 
activity, reduced denervation in the neuromuscular junction and ALS disease symptoms. We 
propose that TDP-43 deregulation contributes to ALS pathogenesis in part by enhancing 
NF-B activation and that NF-B may constitute a therapeutic target for the disease.
© 2011 Swarup et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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In contrast, no p65 was pulled down with TDP-43 using 
extracts of control spinal cords. To further validate TDP- 
43–p65 interaction, we performed reverse coimmunoprecipi-
tation using p65 antibody to immunoprecipitate TDP-43 in 
human spinal cord tissues. Indeed, p65 was able to coimmuno-
precipitate TDP-43 in all nine ALS cases but not in six control 
cases (Fig. S1 A). Along with p65, p50 was also coimmuno-
precipitated with TDP-43 from the spinal cord samples of 
TDP-43WT and TDP-43G348C mice and ALS samples but not 
from nontransgenic or control spinal cord tissues, suggesting 
that TDP-43, p50, and p65 are a part of a complex (Fig. 1 B). 
To determine whether TDP-43 interacts directly with p65 
or p50, we have performed overexpression experiments 
using pCMV expression vectors transfected into mouse neu-
roblastoma Neuro2a cells (Fig. 1 C). Neuro2a cells were 
transfected with pCMV-p65 or pCMV-p50 expression vec-
tors along with vectors encoding either hemagglutinin (HA)-
tagged TDP-43WT or TDP-43NR1-30, a deletion mutant 
lacking the region required for binding to p65 as described in 
the section p65 interacts with the N-terminal and RRM-1 
domains of TDP-43. It should be noted that the cells were 
not stimulated by LPS or any other means. After overexpres-
sion of p65 and TDP-43WT in the Neuro2a cells, p65 was 
coimmunoprecipitated with TDP-43WT but not with TDP-
43NR1-30 using anti-HA antibody. In contrast, p50 was not 
coimmunoprecipitated with TDP-43WT when overexpressed 
alone with TDP-43. These results suggest that TDP-43 inter-
acts directly with p65 but not directly with p50. Immuno-
fluorescence microscopy corroborated these results. In the 
spinal cord of sporadic ALS subjects, p65 was detected pre-
dominantly in the nucleus of cells in colocalization with 
TDP-43 (Fig. 1 D). On the contrary, in control spinal cord, 
there was an absence of p65 in the nucleus, reflecting a lack 
of p65 activation (Fig. 1 D). It is remarkable that microscopy 
of the spinal cord from TDP-43WT transgenic mice revealed 
ALS-like immunofluorescence with active p65 that colocal-
ized perfectly with TDP-43 in the nuclei of cells (Fig. 1 D). 
To elucidate which cell types in the spinal cord of ALS cases 
express TDP-43 and p65, we performed three-color immuno-
fluorescence with CD11b as a microglial-specific marker and 
glial fibrillary acidic protein (GFAP) as an astroglial marker. 
We found that TDP-43 and p65 colocalized in many mi-
croglial and astroglial cells (Fig. 2, D–F, insets). We have 
quantified our data and found that 20 ± 5% of microglia and 
8 ± 3% of astrocytes had TDP-43–p65 colocalization. We 
also found that many of the TDP-43 p65 colocalization was 
in neurons, and some also in motor neurons in many ALS 
cases (Fig. 2, A–C). In many ALS cases in which TDP-43 
formed aggregates in the cytoplasm, p65 was still in the nu-
cleus (Fig. 2, A–C, arrowheads). In nontransgenic C57BL/6 
mice, the lack of p65 activation resulted in partial colocaliza-
tion of TDP-43 with p65 mainly in cytoplasm (Fig. 1 D). 
LPS-stimulated BV-2 cells transfected with pCMV-p65 and 
pCMV–TDP-43WT had most p65 colocalized with nuclear 
TDP-43WT, whereas in unstimulated cells, p65 did not co-
localize with nuclear TDP-43WT. Although p65 was mainly 
understood. TDP-43 is essential for embryogenesis (Sephton 
et al., 2010), and postnatal deletion of the TDP-43 gene in 
mice caused down-regulation of Tbc1d1, a gene which alters 
body fat metabolism (Chiang et al., 2010). Proteins known to 
interact with TDP-43 have also been implicated in protein 
refolding or proteasomal degradation, including ubiquitin, 
proteasome- subunits, SUMO-2/3, and Hsp70 (Seyfried 
et al., 2010).
Because TDP-43 is ubiquitously expressed and several 
studies have supported the importance of glial cells in mediat-
ing motor neuron injury (Clement et al., 2003; Boillée et al., 
2006a,b), we have searched for additional proteins that might 
interact with TDP-43 in LPS-stimulated microglial (BV-2) 
cells. Our rationale for choosing microglial BV-2 cells was 
that TDP-43 deregulation may occur not only in neurons 
but also in microglial cells. Moreover, there are recent reports 
of increased levels of LPS in the blood of ALS patients (Zhang 
et al., 2009a) and of an up-regulation of LPS/TLR-4 signaling–
associated genes in peripheral blood monocytes from ALS 
patients (Zhang et al., 2011). Accordingly, we have biased 
our search for proteins interacting with TDP-43 when micro-
glia are activated by LPS. Surprisingly, coimmunoprecipi-
tation assays and mass spectrometry led us to identify the p65 
subunit of NF-B as a binding partner of TDP-43. Further-
more, we discovered that TDP-43 messenger RNA (mRNA) 
was abnormally up-regulated in the spinal cord of ALS sub-
jects. The results reported here led us to further explore the 
physiological significance of the interaction between TDP-43 
and p65 NF-B.
RESULTS
TDP-43 interacts with the p65 subunit of NF-B
Mass spectrometry analysis and coimmunoprecipitation ex-
periments were performed to identify proteins that interact 
with TDP-43 in mouse microglia (BV-2) cells after LPS stim-
ulation, as described in Materials and methods. Many proteins 
were coimmunoprecipitated with TDP-43, including proteins 
responsible for RNA granule transport (kinesin), molecular 
chaperones (Hsp70), and cytoskeletal proteins (unpublished 
data). In addition, our analysis revealed p65 (REL-A) as a 
novel protein interacting with TDP-43. An interaction be-
tween TDP-43 with p65 NF-B was confirmed by a co-
immunoprecipitation assay with a polyclonal antibody against 
TDP-43 using spinal cord extracts from transgenic mice 
overexpressing human TDP-43WT and TDP-43G348C mutant 
(Swarup et al., 2011) by threefold (Fig. 1 B). Additional co-
immunoprecipitation experiments performed using BV-2 cells 
that were transiently transfected with pCMV–TD-P43WT and 
pCMV-p65 plasmids clearly showed that TDP-43 interacts 
with p65.
To further determine the significance of TDP-43 inter-
action with p65 in the context of human ALS, TDP-43 was 
pulled down with the polyclonal anti–TDP-43 antibody using 
spinal cord extracts from nine sporadic ALS cases and six 
control subjects (Fig. 1 A). In protein extracts from ALS 
cases, p65 NF-B was coimmunoprecipitated with TDP-43. 
JEM Vol. 208, No. 12 
Article
2431
of TDP-43 was studied on gene 
expression of the reporter plasmid 
4BWT-luc by transfecting pCMV–
TDP-43WT in BV-2 cells with or with-
out cotransfection of pCMV-p65 
(Fig. 3 A). When expressed alone, 
TDP-43 had no detectable effect on 
the basal transcription level of plasmid 
4BWT-luc, suggesting that TDP-43 
does not alter the basal transcription 
level of NF-B. However, in co-
expression with p65, TDP-43 aug-
mented the gene expression of plasmid 
4BWT-luc in a dose-dependent man-
ner. 20 ng pCMV-p65 alone activated 
gene expression of 4BWT-luc by 10-fold (Fig. 3 A). How-
ever, upon cotransfection with 20 ng pCMV–TDP-43WT, the 
extent of gene activation was elevated to 22-fold (2.2-fold 
augmentation by the effect of TDP-43). A further increase in 
NF-B–dependent gene expression was recorded as the levels 
of TDP-43WT were elevated to 50 ng (2.8-fold activation) and 
100 ng (3.2-fold activation; n = 4; P < 0.05). When using a 
cytoplasmic in 3-mo-old TDP-43WT spinal cord, there was 
gradual age-dependent p65 activation in 6- and 10-mo-old 
TDP-43WT spinal cord (Fig. S1 D).
TDP-43 acts as a co-activator of p65
A gene reporter assay was performed to study the effect of 
TDP-43 on NF-B–dependent gene expression. The effect 
Figure 1. TDP-43 interacts with NF-B 
p65. (A) Protein extracts from the spinal 
cords of nine sporadic ALS subjects (1–9) and 
six control individuals (1–6) were used for the 
immunoprecipitation (IP) with TDP-43– 
specific polyclonal antibody where indicated. 
Immunoprecipitates or whole cells extracts 
were subjected to immunoblot (IB) with the 
indicated antibodies. Two experiments were 
performed (one with controls 1–5 and ALS 
patients 1–4, and the other with control 6 and 
ALS patients 5–9). (B) Total protein extract 
from spinal cords of TDP-43WT and TDP-
43G348C transgenic mice, B6 nontransgenic 
mice (Ntg), two control individuals, and two 
sporadic ALS patients were subjected to  
immunoprecipitation and immunoblot where 
indicated. (C) Neuro2a cells were transfected 
with pCMV-p65 and pCMV-p50 expression 
vectors along with TDP-43WT or TDP-43NR1-30. 
Extracts were immunoprecipitated with anti–
TDP-43 or control IgG where indicated and 
immunoblotted with anti-p65 and anti-p50. 
(B and C) A representative blot from two in-
dependent experiments is shown. (D) Spinal 
cords of B6 nontransgenic or TDP-43WT trans-
genic mice or control or ALS patients were 
stained with anti-p65 and anti–TDP-43 and 
analyzed by immunofluorescence. Brightness 
and contrast adjustments were made to the 
whole image to make background intensities 
equal in control and ALS cases. The images 
represent at least four sections from two 
experiments using ALS and control patient 
material. Arrows indicate colocalization of 
TDP-43 with p65. Bars, 20 µm.
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was detected. The boosting effects of TDP-43 were not 
caused by increased levels in p65 as shown by immuno-
blotting (Fig. 3 B). Similarly, pCMV–TDP-43A315T and 
control luciferase reporter construct, 4Bmut-luc, in which all 
four B sites were mutated, neither the activation by pCMV-
p65 nor the effect of cotransfection of pCMV–TDP-43WT 
Figure 2. TDP-43 colocalizes with p65 in neuronal and glial cells. (A–C) TDP-43 and p65 double immunofluorescence was performed in different 
sporadic ALS cases as indicated. Double immunofluorescence pictures were taken at various magnifications. Arrowheads represent cytoplasmic localiza-
tion of TDP-43 and nuclear p65 staining. Insets of higher magnification show cytoplasmic localization of TDP-43 and nuclear p65 staining. (D and E) A 
three-color immunofluorescence was performed using rabbit TDP-43, mouse p65, and rat CD11b (marker for microglia) as primary antibodies and Alexa 
Fluor 488 (green), 594 (red), and 633 (far-red, pseudo-color blue) as secondary antibody. Insets of higher magnification show triple colocalization (white) 
of TDP-43–, p65-, and CD11b-positive cells (arrows). (F) A three-color immunofluorescence was performed using rabbit TDP-43, mouse p65, and rat GFAP 
(marker for astrocytes) as primary antibodies and Alexa Fluor 488 (green), 594 (red), and 633 (far-red, pseudo-color blue) as secondary antibody. An inset 
of higher magnification shows triple colocalization (white) of TDP-43–, p65-, and GFAP-positive cells (arrows). (A–F) The images shown are representative 
of at least four sections from two experiments from ALS patients. Bars, 20 µm.
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were transfected in BV-2 cells with pCMV-p65 (Fig. 4 A). 
TDP-43RRM-1 coimmunoprecipitated p65 partially, whereas 
TDP-43RRM-2 and TDP-43C interacted well with p65, 
suggesting that RRM-1 is important but RRM-2 and 
C-terminal domains are dispensable for interaction with p65. 
After transfection, we found that TDP-43N had much re-
duced interaction with p65 (Fig. 4 B), thereby suggesting that 
the N-terminal domain of TDP-43 is essential for the inter-
action of TDP-43 with p65. Because the nuclear localization 
signal is in the N terminus, the reduced interaction of TDP-
43N to p65 could have been the result of a mislocalization of 
TDP-43N. To address this issue and to further define the in-
teracting domain, we constructed a series of N-terminal and 
RRM-1 deletion mutants, TDP-43NR1-81 (98–176 aa), 
TDP-43NR1-50 (51–81 and 98–176 aa), and TDP-43NR1-30 
(31–81 and 98–176 aa), with the nuclear localization signal 
attached so that the mutant proteins are able to be directed to 
the nucleus. Coimmunoprecipitation with these constructs 
suggested that even though TDP-43NR1-30 is in the nucleus 
(Fig. 4 C), it cannot effectively interact with p65, TDP-
43NR1-81, and TDP-43NR1-50, whereas it can interact with 
p65 (Fig. 4 B). These results indicate that TDP-43 interacts 
with p65 through its N-terminal domain (31–81 and 98–106 
aa) and RRM-1 (107–176 aa) domain.
To assess the effect of these deletion mutants on the acti-
vation of NF-B gene, we used the gene reporter assay. Vari-
ous deletion mutants of TDP-43 were cotransfected along 
with 4BWT-luc or 4Bmut-luc. When compared with full-
length TDP-43WT, TDP-43N had reduced effect (twofold; 
n = 3; P < 0.05) on the gene activation. TDP-43RRM-1 also 
exhibited attenuation of gene activation but to a lesser extent 
than TDP-43N (Fig. 4 D). In contrast, TDP-43RRM-2 and 
pCMV–TDP-43G348C augmented p65-mediated gene expres-
sion from the reporter plasmid 4BWT-luc (not depicted).
To further examine the effect of TDP-43 on the activation 
of p65, we performed p65 electrophoretic mobility shift assays 
(EMSAs). Transfection in BV-2 cells of pCMV-p65 with 
pCMV–TDP-43WT or pCMV–TDP-43G348C and LPS treat-
ment was followed by extraction of nuclear proteins. Subse-
quently, the interaction between p65 in the protein extract 
and DNA probe was investigated using the EMSA kit from 
Panomics according to the manufacturer’s instructions. TDP-
43 increased the binding of p65 to the NF-B DNA probe in 
a dose-dependent manner. LPS alone induced the binding of 
p65 to the DNA probe by about twofold as compared with 
control (Fig. 3 C). The cotransfection of 50 and 100 ng TDP-
43WT or of 100 ng TDP-43G348C resulted in a significant dose-
dependent increase in the DNA binding of p65. The specificity 
of the gel shift assay was assessed by adding a cold probe. 
TDP-43 alone did not bind to p65 EMSA probes (Fig. S1 B). 
Moreover, adding an anti-HA antibody that recognizes the 
transfected TDP-43 or an anti-p65 antibody caused supershifts 
of bands in the p65 EMSA (Fig. 3 D). Along with p65 and 
TDP-43, p50 is also part of the activated complex as seen by 
supershifts of bands in p65 EMSA experiments in BV-2 cells 
using antibodies specific to p65, TDP-43, and p50 (Fig. S1 C).
p65 interacts with the N-terminal and RRM-1  
domains of TDP-43
To determine which domains of TDP-43 interact with p65, 
we constructed a series of deletion mutants of various 
TDP-43 domains. Various pCMV-HA–tagged deletion mu-
tants like TDP-43N (1–105 aa), TDP-43RRM-1 (106–176 aa), 
TDP-43RRM-2 (191–262 aa), and TDP-43C (274–414 aa) 
Figure 3. TDP-43 acts as a co-activator of 
NF-B p65. (A) BV-2 cells were transfected with 
20 ng 4BWT-luc (containing WT NF-B–binding 
sites) or 4Bmut-luc (containing mutated NF-B–
binding sites) together with the indicated 
amounts of pCMV–TDP-43WT expression plasmid. 
Cells were harvested 48 h after transfection, and 
luciferase activity was measured. Values represent 
the luciferase activity mean ± SEM of three inde-
pendent transfections, and statistical analysis was 
performed by two-way ANOVA with Bonferroni 
adjustment. TDP-43–transfected BV-2 cells were 
treated with 100 ng/ml LPS. (B) BV-2 cells were 
transfected with 20 ng pCMV-p65 and various 
concentrations of pCMV–TDP-43WT. TDP-43 levels 
are shown when blotted with anti-HA antibody 
(Sigma-Aldrich), and actin is shown as a loading 
control. (C) 48 h after transfection, BV-2 cells 
were harvested, and nuclear extracts were then 
incubated with NF-B p65–binding site–specific 
oligonucleotides coated with streptavidin. EMSA 
was then performed using the NF-B EMSA kit. 
The specificity of the assay was ascertained by adding cold probe. The control lane was performed on a separate EMSA experiment and added. EMSA 
shown is a representative image of two independent experiments. (D) Supershift assay was performed by adding anti-HA antibody, which specifically 
recognizes human TDP-43, during the EMSA assay. p65 antibody was also added in a separate lane as a positive control. Note that all the samples were 
TDP-43 and p65 transfected and LPS stimulated. Supershift EMSA shown is a representative image of two independent experiments.
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transfected in control was more than in other experiments to 
keep similar amounts of total transfected DNA. Transfection 
of a control luciferase reporter construct, 4Bmut-luc, in 
which all four B sites were mutated, had no effect on the 
basal level activation of p65. To determine whether the 
interaction between TDP-43 and p65 is a protein–protein 
interaction, we performed immunoprecipitation experiments 
TDP-43C deletion mutants had effects similar to full-length 
TDP-43WT. As expected, because TDP-43NR1-30 does not 
effectively interact with p65, the level of NF-B activation 
detected by the 4BWT-luc reporter assay was extremely low, 
sixfold lower than full-length TDP-43WT (n = 3; P < 0.001; 
Fig. 4 D). p65 and luciferase vectors were used as controls for 
the experiment. Note that the amount of pCMV-p65 vector 
Figure 4. The N-terminal and RRM-1 
domains of TDP-43 are crucial for inter-
action with p65. (A) Two-dimensional car-
toon of TDP-43 protein showing various 
deletion mutants used in this study. Deletion 
mutants TDP-43N (1–105 aa), TDP-43RRM-1 
(106–176 aa), TDP-43RRM-2 (191–262 aa), and 
TDP-43C (274–414 aa) and full-length  
TDP-43 (TDP-43WT) are shown. Serial N-terminal 
and RRM-1 domain deletion mutants are also 
shown. TDP-43NR1-81 (98–176 aa), TDP-43NR1-50 
(51–81 and 98–176 aa), and TDP-43NR1-30 
(31–81 and 98–176 aa) were generated.  
(B) All constructs (WT and deletion mutants) 
were cloned in pcDNA3.0 with HA tag at the 
extreme C terminus of the encoded protein. 
BV-2 cells were transfected with TDP-43WT or 
deletion constructs and pCMV-p65. 24 h after 
transfection, cells were harvested and immuno-
precipitated (IP) with anti-HA antibody. Im-
munoprecipitates or whole cells extracts  
were subjected to immunoblot (IB) with the 
indicated antibodies. A representative gel 
from three independent experiments is 
shown. (C) BV-2 cells transfected with  
TDP-43WT, TDP-43NR1-50, or TDP-43NR1-30 
were fractionated into nuclear and cytoplas-
mic fractions using sucrose density gradient 
centrifugation. These fractions were then 
probed with anti-HA antibody for the expres-
sion of transfected TDP-43 species. Histone H1 
is used as a nuclear and tubulin as a cytoplas-
mic marker. A representative gel from two 
independent experiments is shown. (D) Vari-
ous deletion mutants of TDP-43 were co-
transfected along with 4BWT-luc (containing 
WT NF-B–binding sites) or 4Bmut-luc (con-
taining mutated NF-B–binding sites). 48 h 
after transfection, luciferase activity was 
measured. Statistical analysis was performed 
by two-way ANOVA with Bonferroni adjust-
ment (*, P < 0.05). Error bars represent mean ± 
SEM from three independent experiments.  
(E) TDP-43 antibody was added to BV-2–
transfected cell lysates, and proteins were 
immunoprecipitated with the indicated anti-
body. After TDP-43 immunoprecipitation, 
samples were treated with 1 µg/ml proteinase K, 
1 µg/ml RNase, or 1 µg/ml DNase 1. To moni-
tor the effectiveness of RNase and DNase 
digestion, RNase or DNase was added to cell lysates before immunoprecipitation and subjected to PCR. GAPDH RT-PCR was used to monitor RNase diges-
tion, whereas Rn18s gene (which codes for 18SrRNA) genomic PCR was used to monitor DNase digestion. Representative blots and gels from three differ-
ent experiments are shown.
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transfected in BM-derived macrophages (BMMs) from normal 
mice. We compared the level of innate immunity activation 
when stimulated with LPS. BMMs transfected with TDP-43 
siRNA had reduced levels of TLR2 mRNA (1.5-fold; P < 
0.05), p65 (threefold; P < 0.01), TNF (threefold; P < 0.01), 
IL-1 (twofold; P < 0.05), IP-10 (twofold; P < 0.05), IL-6 (2.5-
fold; P < 0.01), and Cox-2 (cyclooxygenase-2; twofold; 
P < 0.05) as compared with scrambled siRNA–transfected 
BMMs (Fig. 5 D).
TDP-43 and p65 mRNA levels are up-regulated in the spinal 
cord of sporadic ALS patients
The findings that TDP-43 can interact with p65 and that 
TDP-43 overexpression in transgenic mice was sufficient to 
provoke abnormal nuclear colocalization of p65 as observed 
in sporadic ALS (Fig. 1 D) prompted us to compare the levels 
of mRNA coding for TDP-43 and p65 NF-B in spinal cord 
samples from sporadic ALS cases and control individuals. 
Real-time RT-PCR data revealed that the levels of TDP-43 
mRNA in the spinal cord of sporadic ALS cases (n = 16) were 
up-regulated by 2.5-fold (P < 0.01) compared with controls 
(n = 6; Fig. 6 A). It is also noteworthy that the levels of p65 
NF-B mRNA were up-regulated by about fourfold (P < 
0.001) in ALS cases as compared with controls. Because TDP-43 
forms many bands in Western blot analysis, we quantified 
the total level of TDP-43 protein using sandwich ELISA as 
described in Materials and methods. The ELISA results sug-
gest that TDP-43 protein levels are in fact up-regulated in 
total spinal cord protein extracts of ALS cases (n = 16) by 
1.82-fold (241.2 ± 8.5 pg/µg of total protein) as compared 
with control cases (132.8 ± 5.6 pg/µg of total protein; n = 6; 
Fig. 6 B). For human p65 ELISA, we used an ELISA kit from 
QIAGEN. The levels of p65 were also up-regulated in total 
spinal cord extracts of ALS cases (n = 16) by 3.5-fold (222.5 ± 
11.5 pg/µg of total protein) as compared with control cases 
(62.83 ± 3.8 pg/µg of total protein; n = 6; Fig. 6 C).
by adding proteinase K, RNase A, or DNase 1 (Fig. 4 E). 
The addition of proteinase K abolished the TDP-43–p65 
interaction, whereas RNase A or DNase 1 had no effect, sug-
gesting that the interaction is not DNA/RNA dependent.
TDP-43 small interfering RNA (siRNA) inhibits  
activation of NF-B
If it is correct that TDP-43 acts as a co-activator of p65, then re-
ducing the levels of TDP-43 should attenuate p65 activation. To 
reduce the expression levels of TDP-43, microglial BV-2 cells 
were transfected with either TDP-43 siRNA or scrambled 
siRNA together with 4BWT-luc vectors. 72 h after transfection, 
some of the cells were either stimulated with 100 ng/ml LPS or 
mock stimulated for 12 h. As shown in Fig. 5 A, TDP-43 siRNA 
reduced the endogenous mouse TDP-43 levels significantly as 
compared with scrambled siRNA–transfected cells in two dif-
ferent experiments. To examine the effect of reducing TDP-43 
levels on NF-B activation, BV-2 cells were transfected with 
pCMV-p65 and 4BWT-luc vectors. TDP-43 siRNA decreased 
activation of NF-B reporter gene in transfected cells. The de-
crease in NF-B activation was about threefold for 5 ng pCMV-
p65 (n = 4; P < 0.01), 2.5-fold for 10 and 20 ng pCMV-p65 
(n = 4; P < 0.05), and twofold for 50 ng pCMV-p65 (n = 4; 
P < 0.05) as compared with scrambled siRNA–transfected cells 
(Fig. 5 B). To examine the physiological significance of TDP-43 
inhibition by siRNA, we transfected BV-2 cells with ICAM-1–
luc vector together with TDP-43 siRNA or scrambled siRNA. 
72 h after transfection, cells were stimulated with varying con-
centrations of TNF. When stimulated with 0.5 ng/ml TNF, 
TDP-43 siRNA–transfected cells exhibited a twofold decrease 
in ICAM-1 luciferase activity (n = 4; P < 0.05) as compared 
with cells transfected with scrambled siRNA. Similarly, TDP-43 
siRNA–transfected BV-2 cells exhibited at 1.0- and 1.5-ng/ml 
TNF concentrations a decrease of 2.5-fold (n = 4; P < 0.01) and 
twofold (n = 4; P < 0.05) in ICAM-1 luciferase activity, respec-
tively (Fig. 5 C). We also tested the effect of TDP-43 siRNA 
Figure 5. TDP-43 siRNA inhibits activation of NF-B.  
BV-2 cells were transfected either with mouse TDP-43 siRNA or 
scrambled siRNA. 72 h after transfection, some of the cells were 
either stimulated with 100 ng/ml LPS or mock stimulated for  
12 h. (A) Protein extracted from the siRNA experiment was sub-
jected to Western blot analysis. Mouse endogenous TDP-43  
levels in TDP-43 siRNA or scrambled siRNA were compared in 
two different experiments (expt 1 and expt 2) as determined by 
rabbit polyclonal TDP-43 antibody. (B) Additionally, BV-2 cells 
were transfected with pCMV-p65 (concentrations as indicated) 
and 4BWT-luc vector, and luciferase assay was performed.  
(C) We transfected BV-2 cells with ICAM-1–luc vector in addition 
to TDP-43 siRNA or scrambled siRNA in three different experi-
ments. 72 h after transfection, cells were stimulated with vary-
ing concentrations (as indicated) of TNF. (D) Real-time 
quantitative PCR levels of various mRNAs were compared with 
TDP-43 siRNA–transfected (and LPS stimulated) BMMs and 
scrambled siRNA–transfected (and LPS stimulated) BMMs.  
(B-D) Statistical analysis was performed by two-way ANOVA 
with Bonferroni adjustment (*, P < 0.05; **, P < 0.01). Error bars 
represent mean ± SEM from three different experiments.
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Similarly, in response to LPS, the extra levels of TDP-43 spe-
cies in transfected microglial cells caused a significant fivefold 
increase (n = 5; P < 0.001) in the mRNA levels of IL-1 
(Fig. 8 A) and ninefold increase in mRNA levels of IL-6 
(n = 5; P < 0.001; Fig. 7 B) as compared with LPS-treated 
mock-transfected cells. The levels of NADPH oxidase 2 
(Nox-2 gene) was increased by 2.8-fold (n = 5; P < 0.05; 
Fig. 8 B) in LPS-challenged TDP-43–transfected cells as 
compared with LPS-treated mock-transfected cells. Remark-
ably, overexpression of TDP-43 species resulted in a 10-fold 
(n = 5; P < 0.001) increase in levels of p65 (RELA) mRNA 
in LPS-treated transfected cells as compared with LPS-treated 
mock-transfected cells (Fig. 7 C). Note that, in the absence 
of LPS stimulation, microglial cells transfected with TDP-43 
species (both WT and mutants) exhibited no significant dif-
ferences in levels of TNF, IL-1, Nox-2, and NF-B when 
compared with mock-transfected controls.
To further evaluate the effect of LPS stimulation in TDP-
43–overexpressing microglia, we prepared primary microglial 
cultures from C57BL/6 mice and from transgenic mice over-
expressing TDP-43WT by threefold. Primary microglial cells 
were challenged with LPS at a concentration of 100 ng/ml of 
media. 12 h after LPS challenge, cells were harvested, and 
total protein was extracted and used for multianalyte ELISA. 
LPS-treated TDP-43WT transgenic microglia had significantly 
higher levels of TNF (2.5-fold; P < 0.01), IL-1 (2.3-fold; 
P < 0.01), IL-6 (twofold; P < 0.05), and IFN- (twofold; P < 
0.05) as compared with LPS-treated microglia from C57BL/6 
nontransgenic mice (Fig. 7 D). However, in the absence of 
LPS stimulation, no significant differences in cytokines levels 
were detected between microglia from TDP-43WT transgenic 
mice and from nontransgenic mice (not depicted). The p65 
level was significantly higher (threefold; P < 0.01) in LPS-
treated TDP-43WT microglia as compared with nontransgenic 
microglia (Fig. 7 D). We also treated primary microglial cul-
tures with 1 mM H2O2 for 1 h (and incubated in serum-free 
media for 12 h) to study the effect of reactive oxygen species 
(ROS) on primary microglial cultures. H2O2-treated TDP-
43WT transgenic microglia had significantly higher levels of 
TNF (threefold; P < 0.01), IL-1 (2.5-fold; P < 0.01), IL-6 
(1.7-fold; P < 0.05), IFN- (twofold; P < 0.05), and p65 
(RELA) levels (2.2-fold; P < 0.05) when compared with 
H2O2-treated microglia from C57BL/6 nontransgenic mice 
(Fig. 7 E) as determined by multianalyte ELISA.
LPS stimulation of primary microglial cells caused deg-
radation of IB- as shown in Fig. 7 G. The decrease in 
IB- levels was more pronounced in microglia overex-
pressing TDP-43 species. After LPS treatment, the increases 
in levels of p65, phospho-p65Ser536, p50, and phospho-
p50Ser337 were also more robust in transgenic microglia 
overexpressing TDP-43 species (Fig. 7 G). Similarly, H2O2 
treatment led to a reduction in IB- levels and increase in 
levels of p65 and phospho-p65Ser536 in TDP-43WT (Fig. 8 C). 
Again, the effects were more pronounced in transgenic 
microglia overexpressing TDP-43 species (Fig. 8 C). We 
then treated primary astrocytes with LPS and studied their 
TDP-43 overexpression in glia or macrophages causes 
hyperactive inflammatory responses to LPS
Because NF-B is involved in proinflammatory and innate 
immunity response, we tested the effects of increasing TDP-43 
mRNA expression in BV-2 cells. Because LPS is a strong 
proinflammatory stimulator (Horvath et al., 2008), we used it 
to determine the differences in levels of proinflammatory cyto-
kines produced by TDP-43–transfected or mock-transfected 
BV-2 cells. BV-2 cells were transiently transfected with 
pCMV–TDP-43WT, pCMV–TDP-43A315T, pCMV–TDP-
43G348C, or empty vector. 48 h after transfection and 12 h 
after 100-ng/ml LPS challenge, RNA extracted from vari-
ous samples was subjected to real-time quantitative RT-PCR 
to determine the mRNA levels of various proinflammatory 
genes. As expected, there was a fourfold increase in mRNA 
levels of TNF after LPS stimulation of BV-2 cells compared 
with controls (Fig. 7 A). However, in LPS-treated cells trans-
fected with WT TDP-43, there was an additional three-
fold (n = 5; P < 0.05) increase in TNF levels. TDP-43 
harboring the A315T and G348C mutations had similar 
effects on boosting the levels of TNF upon LPS stimulation. 
Figure 6. Analysis of TDP-43 and NF-B p65 mRNA expression in 
sporadic ALS spinal cord. (A) Spinal cord tissue samples from 16 differ-
ent sporadic ALS patients and 6 controls were subjected to real-time RT-
PCR analysis using primers specific for TDP-43 (TARDBP) and p65 (RELA). 
All real-time RT-PCR values are normalized to Atp-5 levels. (B) Sandwich 
ELISA was performed for TDP-43 using TDP-43 monoclonal and poly-
clonal antibodies. After coating the ELISA plates with TDP-43 monoclonal 
antibody, the plates were incubated with the protein lysates (containing 
both soluble and insoluble fragments in between) followed by TDP-43 
polyclonal antibody and subsequent detection. (C) For p65 ELISA, an ELISA 
kit from QIAGEN was used. (A–C) Statistical analysis was performed using 
the unpaired Student’s t test with Welch’s correction (*, P < 0.01;  
**, P < 0.001). Error bars represent mean ± SEM from three  
different experiments.
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compared with LPS-treated microglia from C57BL/6 non-
transgenic mice (Fig. 7 F).
To further evaluate the innate immune response in 
TDP-43WT transgenic mice, we isolated BMMs from TDP-
43WT transgenic mice and from C57BL/6 nontransgenic 
mice. In LPS-stimulated TDP-43WT macrophages, there 
response to LPS using real-time RT-PCR. LPS-treated 
TDP-43WT transgenic astrocytes had significantly higher 
levels of IL- (1.75-fold; P < 0.05), IL-1 (1.67-fold; P < 
0.05), IL-6 (2.8-fold; P < 0.01), IL-18 (1.8-fold; P < 0.05), 
and chemokines like CSF (1.6-fold; P < 0.05), CCL5 (1.9-
fold; P < 0.05), and CXCL12 (2.67-fold; P < 0.01) as 
Figure 7. Analysis of genes involved in inflammation of mouse microglial and macrophage cells overexpressing human TDP-43. (A–C) Mouse 
microglial cells BV-2 were either transfected with pCMV–TDP-43WT, pCMV–TDP-43A315T, and pCMV–TDP-43G348C or with empty vectors for 48 h. These cells 
were then either stimulated with LPS at a concentration of 100 ng/ml or unstimulated (as indicated). 12 h after stimulation, total RNA was extracted with 
TRIZOL. The total RNA samples were then subjected to real-time quantitative RT-PCR for TNF (A), IL-6 (B), and Rel-A (p65; C). Error bars represent mean ± 
SEM from five different experiments. (D) Primary microglial cultures from TDP-43WT and B6 nontransgenic mice were stimulated with 100 ng/ml LPS. 
Proteins from LPS-stimulated microglial cultures were subjected to multianalyte ELISA for inflammatory cytokines and p65. Error bars represent mean ± 
SEM from four different experiments. (E) Primary microglial cultures from TDP-43WT and B6 nontransgenic mice were treated with 1 mM H2O2 for 1 h and 
incubated in serum-free media for 12 h to study the effect of ROS. (F) Pure (>90%) primary astrocytes from TDP-43WT and B6 nontransgenic mice were 
stimulated with LPS and their response studied using real-time PCR for various genes as indicated. (E and F) Error bars represent mean ± SEM from three 
different experiments. (G) Primary microglial cells from TDP-43WT, TDP-43A315T, TDP-43G348C, and B6 nontransgenic mice (Ntg) were stimulated or unstimu-
lated with LPS. Immunoblots were run to determine the levels of various proteins using specific antibodies as indicated. A representative blot from two 
independent experiments is shown. (H) BMMs isolated from TDP-43WT and B6 nontransgenic mice were stimulated with 100 ng/ml LPS for 12 h. Total 
RNA samples were then subjected to real-time quantitative RT-PCR for various genes as indicated. Results are displayed as fold change over unstimulated 
control. All real-time RT-PCR values are normalized to Atp-5 levels. Error bars represent mean ± SEM from four different experiments. (A–F and H) Statis-
tical analysis was performed by two-way ANOVA with Bonferroni adjustment (*, P < 0.05; **, P < 0.01).
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in TNF, 3.5-fold in IL-1 (P < 0.01), and 2.6-fold in IL-12p40 
levels, 2.5-fold (P < 0.01) in IL-6 levels, twofold (P < 0.05) 
in Cox-2 and iNOS levels, threefold in IP-10 levels (P < 
0.01), and 2.1-fold in RANTES (P < 0.05) mRNA levels 
as compared with LPS-stimulated control (nontransgenic) 
macrophages (Fig. 7 H).
was an increase of 1.6-fold (P < 0.05) in TLR2 mRNA 
levels, 1.8-fold (P < 0.05) in MyD88 levels, and 2.6-fold 
(P < 0.01) in p65 (RELA; P < 0.01) levels as compared 
with LPS-stimulated control (nontransgenic) macrophages 
(Fig. 7 H). We also found in LPS-stimulated TDP-43WT 
macrophages that there was an increase of 3.2-fold (P < 0.01) 
Figure 8. TDP-43 up-regulation enhances neuronal vulnerability to death by microglia-mediated cytotoxicity. (A and B) TDP-43 (WT and  
mutants)–transfected BV-2 cells were stimulated with LPS. 12 h after stimulation, total RNA was extracted with TRIZOL. The total RNA samples were then 
subjected to real-time quantitative RT-PCR for IL-1 (A) and Nox-2 (B). Error bars represent mean ± SEM from five different experiments. Statistical analy-
sis was performed by two-way ANOVA with Bonferroni adjustment. (C) Primary microglial cells from TDP-43WT, TDP-43A315T, TDP-43G348C, and B6 non-
transgenic mice (Ntg) were stimulated or unstimulated with H2O2. Immunoblots were run to determine the levels of various proteins using specific 
antibodies as indicated. A representative blot from two independent experiments is shown. (D–F) Primary cortical neurons from TDP-43WT, TDP-43A315T, 
TDP-43G348C, and control B6 nontransgenic mice were incubated with the conditioned media (con. media) derived from primary microglial cells treated 
with 100 ng/ml LPS. 12 h after challenging cortical cells, cell culture supernatants were used for LDH assay (D). ROS production was determined by H2D-
CFDA fluorescence (E), and nitrite production was evaluated by Griess reagent (F). Error bars represent mean ± SEM from four independent experiments.
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with the conditioned media from primary microglial cul-
ture, which were challenged with LPS at a concentration of 
100 ng/ml of media. Treatment of neuronal cultures with WA 
resulted in substantial decrease in microglia-mediated death 
of neurons overexpressing TDP-43WT (twofold; P < 0.01), 
TDP-43A315T (threefold; P < 0.01), or TDP-43G348C (three-
fold; P < 0.01). As WA might exert multiple pharmacologi-
cal actions, we tested a more specific molecular approach for 
inhibiting NF-B. Because activation of NF-B requires its 
dissociation from the inhibitory molecule, IB, we expressed 
a stable mutant super-repressive form of IB- (Ser32/Ser36 
to alanine mutant; IBSR) and evaluated its effects on neuro-
nal death. Cultured cortical neurons from TDP-43 transgenic 
and nontransgenic mice were transfected with a plasmid con-
struct, expressing IBSR, and exposed to either 10 µM gluta-
mate for 30 min or incubated in conditioned media from 
LPS-stimulated microglia of the same genotype. Similar to 
WA treatment, we found that IBSR inhibited NF-B acti-
vation and it attenuated the glutamate-induced or microg-
lia-mediated death of neurons overexpressing TDP-43WT 
(1.3-fold; P < 0.01), TDP-43A315T (1.5-fold; P < 0.01), and 
TDP-43G348C (twofold; P < 0.01; Fig. 9, A and D).
NF-B inhibition by WA treatment reduces inflammation and 
ameliorates motor impairment of TDP-43 transgenic mice
To study the in vivo effect of NF-B inhibition on disease 
progression, we injected TDP-43WT;GFAP-luc double trans-
genic mice with 3 mg/kg body weight of WA twice a week 
for 10 wk starting at 30 wk. The pharmacokinetic parameters 
of WA have been published recently (Thaiparambil et al., 
2011), and we have determined that this compound passes 
the blood–brain barrier (unpublished data). We used TDP-
43WT;GFAP-luc double transgenic mice because the reporter 
luciferase allowed the longitudinal and noninvasive biopho-
tonic imaging with charge-coupled device camera of the 
GFAP promoter activity, which is a target of activated NF-B. 
To analyze the spatial and temporal dynamics of astrocyte 
activation/GFAP induction in the TDP-43 mouse model, 
we performed a series of live imaging experiments. These live 
imaging experiments revealed that treatment of TDP-43WT; 
GFAP-luc mice with WA caused progressive reduction in 
GFAP-luc expression in the spinal (Fig. 9, B and C) com-
pared with untreated TDP-43WT mice, which continued to 
exhibit high GFAP-luc expression. The down-regulation of 
GFAP promoter activity was further confirmed in these mice 
using GFAP immunofluorescence of spinal cord sections of 
TDP-43WT mice (both drug treated and untreated; Fig. 9 F).
This down-regulation of GFAP in WA-treated mice was 
actually caused by a reduced amount of active p65 in the 
nucleus of cells as indicated by p65 EMSA (Fig. 10 C). 
Down-regulation of GFAP along with reduction in active 
p65 levels in WA-treated mice prompted us to analyze behav-
ioral changes in these mice. Analysis of motor behavior using 
accelerating rotarod showed that WA-treated TDP-43WT 
mice had significantly better motor performance compared 
with untreated TDP-43WT mice as indicated by improved 
TDP-43 up-regulation increases  
microglia-mediated neurotoxicity
We then examined the effect of TDP-43 overexpression on 
toxicity of microglia toward neuronal cells. This was done with 
the use of primary microglia and of cortical neurons derived 
from transgenic mice overexpressing TDP-43 species (TDP-
43WT, TDP-43A315T, or TDP-43G348C) and C57BL/6 nontrans-
genic mice. Primary cortical neurons were cultured for 12 h in 
conditioned media from LPS-stimulated microglial cells. All 
conditioned media from LPS-challenged microglia increased 
the death of cortical neurons in culture (Fig. 8 D). The media 
from LPS-stimulated nontransgenic microglial cells increased 
the neuronal death of nontransgenic mice by 3.5-fold (P < 
0.01). However, there were marked increases of neuronal death 
caused by conditioned media from LPS-challenged microglia 
(of same genotype) overexpressing TDP-43 species: 5.5-fold 
(P < 0.001) for TDP-43WT, 6.5-fold (P < 0.001) for TDP-43A315T, 
and 7.5-fold (P < 0.001) for TDP-43G348C. The increased neu-
rotoxicity of the conditioned media was associated with in-
creased ROS and NO production. The ROS production, as 
determined by H2DCFDA fluorescence, was significantly 
higher in conditioned media–challenged neurons from TDP-
43WT (1.5-fold; P < 0.05), TDP-43A315T (1.8-fold; P < 0.05), or 
TDP-43G348C (twofold; P < 0.05) as compared individually with 
conditioned media–challenged nontransgenic control neurons 
(Fig. 8 E). Similarly, the nitrite (NO) production was signifi-
cantly higher in TDP-43WT (1.5-fold; P < 0.05), TDP-43A315T 
(2.3-fold; P < 0.05), or TDP-43G348C (threefold; P < 0.01) as 
compared individually with nontransgenic control (Fig. 8 F).
Inhibition of NF-B activation reduces vulnerability  
of TDP-43–overexpressing neurons to toxic injury
The aforementioned experiments also revealed that the pres-
ence of TDP-43 transgenes in cortical neurons increased 
their vulnerability to microglia-mediated toxicity. NF-B is 
known to modulate p53-p38MAPK–dependent apoptosis in 
neurons when treated with DNA damage–inducing chemi-
cals like camptothecin (Aleyasin et al., 2004), glutamate exci-
totoxicity (Pizzi et al., 2005), or general bystander-mediated 
killing of neurons by microglia (Sephton et al., 2010). To as-
sess the potential contribution of NF-B to the death of 
TDP-43–overexpressing neurons exposed to toxic injury, we 
prepared cultures of primary cortical neurons and microglia 
from transgenic mice overexpressing TDP-43WT or TDP-43 
mutants. Cortical neurons were exposed to 10 µM glutamate 
for 15 min, with or without 1 µM Withaferin A (WA), a 
known inhibitor of NF-B (Oh et al., 2008). The lactate de-
hydrogenase (LDH) cytotoxicity was determined 24 h later 
(see Fig. 10 A). We found that neurons overexpressing 
TDP-43 species were more vulnerable than nontransgenic 
neurons to glutamate cytotoxicity and that inhibition of NF-B 
by WA resulted in a marked decrease in cell death: TDP-43WT 
(twofold; P < 0.01), TDP-43A315T (threefold; P < 0.01), and 
TDP-43G348C (threefold; P < 0.01). The addition of WA in-
hibited NF-B, as detected by reduced levels of phospho-
p65Ser536 (see Fig. 10 B). We then incubated cortical neurons 
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Figure 9. Inhibition of NF-B reduces neuronal vulnerability to toxic injury and ameliorates disease phenotypes in TDP-43 transgenic mice. 
(A) A stable mutant super-repressive form of IB- (IBSR) was expressed, and its effects on neuronal death were evaluated. The phosphorylation- 
defective IB-S32A/S36A acts by sequestering the cytoplasmic NF-B pool in a manner that is insensitive to extracellular stimuli. Cultured cortical neurons 
from TDP-43WT, TDP-43A315T, TDP-43G348C, and B6 nontransgenic mice were transfected with a plasmid construct, expressing IBSR, and exposed to either 
10 µM glutamate for 30 min or incubated in conditioned media from LPS-stimulated microglia of the same genotype. Cytotoxicity to the cells was mea-
sured by LDH assay using a commercially available kit. Statistical analysis was performed by two-way ANOVA with Bonferroni adjustment (*, P < 0.05;  
**, P < 0.01). Data represent mean ± SEM from three independent experiments. (B) In vivo bioluminescence imaging of astrocyte activation was analyzed 
at various time points in the spinal cord of GFAP-luc/TDP-43WT mice. Typical sequence of images of the spinal cord area obtained from of GFAP-luc/TDP-43WT 
mice at different time points (12, 32, 36, and 40 wk) by in vivo imaging (n = 10 each group). WA was injected in GFAP-luc/TDP-43WT for 10 wk starting at 
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that underlies a 2.5-fold increase in TDP-43 mRNA levels in 
ALS, whether it is transcriptional or mRNA stability, remains 
to be investigated. It seems unlikely that copy number variants 
could explain an increase of TDP-43 gene transcription as 
variations in copy number of TARDBP have not been de-
tected in cohorts of ALS (Guerreiro et al., 2008; Bäumer et al., 
2009; Gitcho et al., 2009). Actually, the pathogenic pathways 
of TDP-43 abnormalities in ALS are not well understood. 
To date, much attention has been focused on cytoplasmic 
C-terminal TDP-43 fragments that can elicit toxicity in cell 
culture systems (Johnson et al., 2008; Dormann et al., 2009; 
Igaz et al., 2009; Zhang et al., 2009b). However, it is note-
worthy that neuronal overexpression at high levels of WT or 
mutant TDP-43 in transgenic mice caused a dose-dependent 
degeneration of cortical and spinal motor neurons but without 
massive cytoplasmic TDP-43 aggregates (Wils et al., 2010). 
This suggests that an up-regulation of TDP-43 in the nucleus 
rather than TDP-43 cytoplasmic aggregates may contribute to 
neurodegeneration in these mouse models. As shown in this 
study, an overexpression of TDP-43 can trigger pathogenic 
pathways via NF-B activation.
The transcription factor NF-B is a key regulator of 
hundreds of genes involved in innate immunity, cell sur-
vival, and inflammation. Because the nuclear translocation 
and DNA binding of NF-B are not sufficient for gene 
induction (Yoza et al., 1996; Bergmann et al., 1998), it has 
been suggested that interactions with other protein mole-
cules through the transactivation domain (Schmitz et al., 
1995b; Gerritsen et al., 1997; Perkins et al., 1997) as well as 
its modification by phosphorylation (Schmitz et al., 1995a) 
might play a critical role. It has been reported that transcrip-
tional activation of NF-B requires multiple co-activator pro-
teins including CBP (CREB-binding protein)/p300 (Gerritsen 
et al., 1997; Perkins et al., 1997), CBP-associated factor, and 
steroid receptor co-activator 1 (Sheppard et al., 1999). These 
co-activators have histone acetyltransferase activity to mod-
ify the chromatin structure and also provide molecular 
bridges to the basal transcriptional machinery. NF-B p65 
was also found to interact specifically with FUS (fused in 
sarcoma) protein, another DNA/RNA-binding protein 
rotarod testing times (Fig. 9 D). We performed peripherin 
immunofluorescence and found reduction of peripherin ag-
gregates in WA-treated TDP-43WT mice (Fig. 9 E). Periph-
erin levels were also reduced in WA-treated TDP-43WT mice 
as seen by immunoblot (Fig. 10 E). Double immunofluores-
cence of activated microglial marker Mac-2 and Cox-2 
showed a marked reduction in activated microglia in WA-
treated TDP-43WT mice (Figs. 9 E and 10 F). The WA-treated 
mice also had a 40% reduction in the number of partially de-
nervated neuromuscular junctions (NMJs; Fig. 9, E and G).
DISCUSSION
From the data presented in this study, we propose that a TDP-
43 deregulation in ALS may contribute to pathogenic path-
ways through abnormal activation of p65 NF-B. Several lines 
of evidence support this scheme: (a) proof of a direct inter-
action between TDP-43 and p65 NF-B was provided by im-
munoprecipitation experiments using protein extracts from 
cultured cells, from TDP-43 transgenic mice, and from human 
ALS spinal cord samples; (b) reporter gene transcription assays 
and gel shift experiments demonstrated that TDP-43 was act-
ing as a co-activator of p65 NF-B through binding of its 
N-terminal and RRM-1 domains to p65; (c) the levels of 
mRNAs for both TDP-43 and p65 NF-B were substantially 
elevated in the spinal cord of ALS subjects as compared with 
non-ALS subjects, whereas immunofluorescence microscopy of 
ALS spinal cord samples revealed an abnormal nuclear localiza-
tion p65 NF-B; (d) cell transfection experiments demonstrated 
that an overexpression of TDP-43 can provoke hyperactive 
innate immune responses with ensuing enhanced toxicity on 
neuronal cells, whereas in neurons TDP-43 overexpression in-
creased their vulnerability to toxic environment; and (e) in 
vivo treatment of TDP-43 transgenic mice with an inhibitor of 
NF-B reduced inflammation and ameliorated motor deficits.
This is the first report of an up-regulation of mRNAs en-
coding TDP-43 in postmortem frozen spinal cords of sporadic 
ALS. A recent study has provided evidence of increased TDP-
43 immunodetection in the skin of ALS patients (Suzuki et al., 
2010), but it failed to demonstrate whether this was caused 
by up-regulation in TDP-43 mRNA expression. The process 
30 wk of age until 40 wk. Representative images are shown. (C) Longitudinal quantitative analysis of the total photon GFAP signal/ bioluminescence (total 
flux of photon/s) in WA-treated and untreated GFAP-luc/TDP-43WT mice and control GFAP-luc mice in the spinal cord is displayed. Duration of drug treat-
ment is indicated. (D) Accelerating rotarod analysis was performed in GFAP-luc/TDP-43WT mice at various ages from 8 wk to 52 wk, and time taken by the 
mice to fall from the rotarod is used as rotarod performance. WA treatment period is marked as drug treatment period. (C and D) Asterisks represent a 
statistically significant difference between treated and untreated groups (*, P < 0.05; and **, P < 0.01) using repeated measures two-way ANOVA.  
(C and D) Error bars represent mean ± SEM (n = 10 each group). (E) Immunofluorescence of spinal cord sections of nontransgenic (Ntg; control), TDP-43WT  
(untreated), and TDP-43WT (WA treated) mice with polyclonal peripherin antibody is shown. Double immunofluorescence of spinal cord sections with acti-
vated microglial marker Mac-2 and Cox-2 is shown. Representative images from four different mice per genotype are shown. NMJ staining was per-
formed using anti-synaptophysin/neurofilament antibodies (green) and -bungarotoxin (BTX; red). Representative images from four different mice per 
genotype showing fully innervated muscle in 10-mo-old nontransgenic mice, fully denervated muscle in TDP-43WT mice (untreated), and partially dener-
vated muscle in age-matched WA-treated TDP-43WT mice. (F) Immunofluorescence using GFAP antibody was performed in the spinal cord sections of 
WA-treated and untreated GFAP-luc/TDP-43WT mice. Representative images from five different mice per genotype are shown. (G) 300 NMJs were counted 
per animal sample. Frequencies of innervation, partial denervation, and denervation were then converted to percentages and plotted as a graph. Statisti-
cal analysis was performed by the Student’s t test. The asterisk represents a statistically significant difference between treated and untreated groups  
(*, P < 0.01) using repeated measures two-way ANOVA. Error bars represent mean ± SEM from three different experiments. Bars, 20 µm.
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resulting in enhanced toxicity toward neighboring neuronal 
cells with involvement of ROS and increased nitrite levels 
(NO). Moreover, the adverse effects of TDP-43 up-regulation 
are not limited to microglial cells. TDP-43 overexpression in 
transgenic astrocytes caused exaggerated responses to LPS 
(Fig. 7 F), whereas primary cortical neurons overexpressing 
TDP-43 transgenes by approximately threefold exhibited in-
creased susceptibility to the toxic effects of excess glutamate or 
LPS-activated microglia (Figs. 8 D and 9 A).
which is involved in ALS (Kwiatkowski et al., 2009; Vance 
et al., 2009; Deng et al., 2010).
Our results revealed robust effects of TDP-43 on the acti-
vation of NF-B and innate immune responses. After trans-
fection with TDP-43 species, microglial cells challenged with 
LPS exhibited much higher mRNA levels for proinflamma-
tory cytokines, Nox-2, and NF-B mRNA when compared 
with untransfected cells after LPS stimulation. TDP-43 over-
expression makes microglia hyperactive to immune stimulation, 
Figure 10. WA ameliorates TDP-43–mediated toxicity. (A) Primary cortical neurons from TDP-43WT, TDP-43A315T, TDP-43G348C, and B6 nontransgenic 
mice were exposed to 10 µM glutamate for 15 min or incubated in conditioned media from LPS-stimulated microglia of the same genotype with or with-
out 1 µM WA and were evaluated for LDH cytotoxicity 24 h later. Asterisks represent a statistically significant difference between treated and untreated 
groups (*, P < 0.05; and **, P < 0.01) using repeated measures two-way ANOVA. Error bars represent mean ± SEM from three independent experiments. 
(B) Protein samples from cortical neurons (isolated from TDP-43WT, TDP-43A315T, TDP-43G348C, and B6 nontransgenic [Ntg] mice) were subjected to immuno-
blot against various antibodies as indicated. (C) p65 EMSA was performed on the spinal cord tissue nuclear lysates from WA-treated and untreated GFAP-
luc/TDP-43WT mice. A representative EMSA of two independent experiments is shown. (D) IB levels were measured by Western blot analysis of the cell 
lysates from cortical neurons of various genotypes as indicated. Actin is shown as loading control. Various conditions are also shown. (E) Western blot 
analysis of spinal cord sections of nontransgenic (control), TDP-43WT (untreated), and TDP-43WT (WA treated) mice with monoclonal peripherin antibody. 
(D and E) A representative blot from two different experiments is shown. (F) Quantification of microglial Mac-2–positive cells in the spinal cord sections 
of nontransgenic (control), TDP-43WT (untreated), and TDP-43WT (WA treated) mice. Mac-2+ cells in TDP-43WT (untreated) L5 spinal cord, 13,000 ± 500/mm3; 
and TDP-43WT (WA treated) L5 spinal cord, 6,000 ± 300/mm3 (**, P < 0.001). Error bars represent mean ± SEM for four mice of each genotype.
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signaling (Badadani et al., 2010; Custer et al., 2010). Moreover, 
some ALS-linked mutations have been discovered in the gene 
coding for optineurin, a protein which activates the suppressor 
of NF-B (Maruyama et al., 2010), further supporting a con-
vergent NF-B pathogenic pathway. Thus, the data presented 
in our paper as well as ALS-linked mutations in the VCP and 
optineurin genes (Badadani et al., 2010; Johnson et al., 2010; 
Maruyama et al., 2010) are all supporting a convergent NF-B 
pathogenic pathway in ALS. Recently, the NF-B signaling 
complex was identified as a major contributor of astrocyte 
mediated toxicity to motor neurons (Haidet-Phillips et al., 
2011). In this study, we show that inhibitors of NF-B activa-
tion are able to attenuate the vulnerability of cultured neurons 
overexpressing TDP-43 species to glutamate-induced or 
microglia-mediated toxicity. Moreover, pharmacological in-
hibition of NF-B by WA treatment attenuated disease phe-
notypes in TDP-43 transgenic mice. From these results, we 
propose that NF-B signaling should be considered as a po-
tential therapeutic target in ALS treatment.
MATERIALS AND METHODS
Human subjects. The spinal cords of 16 subjects with sporadic ALS and 6 
control cases were used in this study. The diagnosis of ALS was made on both 
clinical and pathological grounds. The ages at death ranged from 42 to 79 yr, 
and the duration of illness ranged from 21 to 48 mo (Table S3). TDP-43–
positive inclusions were found in all ALS cases. We also used spinal cord samples 
from six neurologically normal individuals (normal controls), aged between 
55 and 84 yr. For routine histological examination, the spinal cord of each 
subject was fixed with 10% buffered formalin for 3 wk and then embedded in 
paraffin; 4-µm-thick sections were cut and stained with hematoxylin. The use 
of the human tissue samples described in this article was performed in accor-
dance to the Committee on Research Ethics of Enfant-Jesus Hospital.
Generation of TDP-43 transgenic mice. TARDBP (GenBank/EMBL/
DDBJ accession no. NM_007375) was amplified by PCR from a human 
BAC clone (clone RPCI-11, clone number 829B14) along with the endoge-
nous promoter (4 kB). A315T and G348C mutations in TDP-43 were in-
serted using site-directed mutagenesis. The full-length genomic TARDBP 
(TDP-43WT and TDP-43G348C) was linearized by Swa1 restriction enzyme 
and 18-kb DNA fragment microinjected in 1-d-old mouse embryos (having 
a background of C3H × C57BL/6). The embryos were implanted in pseudo-
pregnant mothers (having ICR CD1 background). Founders were bred with 
nontransgenic C57BL/6 mice to establish stable transgenic lines (Swarup et al., 
2011). Transgene expression was analyzed in brain and spinal cord by real-
time PCR and in brain, spinal cord, muscle, and liver by Western blotting 
using monoclonal human TDP-43 antibody (clone E2-D3; Abnova). All ex-
perimental procedures were approved by the Laval University Animal Care 
Ethics Committee and are in accordance with the Guide to the Care and Use 
of Experimental Animals of the Canadian Council on Animal Care.
WA treatment. WA (Enzo Life Sciences) was injected intraperitoneally 
twice a week for 10 consecutive weeks at 3 mg/kg body weight in 30-wk-old 
TDP-43WT mice (n = 10). Age-matched control nontransgenic animals 
(n = 10) and TDP-43WT (n = 10) littermates were injected twice a week with 
0.9% saline intraperitoneally. All of the behavioral and imaging experiments 
were conducted in a double blind manner, and as such the experimenter had 
no knowledge of the drug treatment or the genotype of animals.
Plasmids. Mammalian expression vector plasmids pCMV-p65, pCMV-
p50, and ICAM1–luc (positions 340 to 25) and luciferase reporter plas-
mids 4BWT-luc or 4Bmut-luc, containing four tandem copies of the human 
immunodeficiency virus-B sequence upstream of minimal SV40 promoter, 
The presence of ALS-linked mutations in TDP-43 (A315T 
or G348C) did not affect the binding and activation of p65 
NF-B. This is not surprising because our deletion mutant 
analysis revealed that a region spanning part of the N-terminal 
domain and RRM-1 of TDP-43 is responsible for interaction 
with p65, whereas most TDP-43 mutations in ALS occur in 
the C-terminal domain, which is dispensable for p65 NF-B 
activation (Fig. 4). In fact, our cytotoxicity assays with pri-
mary cells from TDP-43 transgenic mice revealed that, at 
similar levels of mRNA expression, the adverse effects of mu-
tant TDP-43 were more pronounced than TDP-43WT. These 
results could be explained by the observation that ALS-linked 
mutations in TDP-43 increase its protein stability (Ling et al., 
2010). From the data presented here, we propose the involve-
ment in ALS of a pathogenic pathway caused by nuclear in-
crease in TDP-43 levels (Fig. 6). This scheme does not exclude 
adverse effects caused by cytoplasmic TDP-43 aggregates that 
might occur concomitantly or later on during the disease pro-
cess. A recent TDP-43 study with Drosophila melanogaster sug-
gested that the TDP-43 toxicity may occur in the absence 
of inclusions formation and that neurotoxicity requires the 
TDP-43 RNA–binding domain (Voigt et al., 2010). These 
results are consistent with our model of TDP-43 toxicity and 
with data demonstrating the interaction of TDP-43 with p65 
via the RNA recognition motif RMM-1.
Our finding that TDP-43 acts as co-activator of p65 sug-
gests a key role for NF-B signaling in ALS pathogenesis. 
This is corroborated by the abnormal fourfold increase of p65 
NF-B mRNA in the spinal cord of human ALS (Fig. 6) and 
by the nuclear localization of p65 (Fig. 1 D and Fig. 2, insets). 
Remarkably, an overexpression of TDP-43 species by approx-
imately threefold in transgenic mice (Swarup et al., 2011), at 
levels similar to the human ALS situation (2.5-fold), was suf-
ficient to cause nuclear translocation of p65 NF-B in the 
spinal cord during aging (Fig. 1 D). It should be noted that 
TDP-43 itself does not cause NF-B activation (Fig. 7) and 
that it does not up-regulate p65. It seems that a second hit is 
required. For example, LPS or other inducers such as pathogen-
associated molecular patterns can trigger through TLR sig-
naling p65 NF-B nuclear localization. Cytokines such as 
TNF and IL-1 can also trigger p65 activation. In ALS, the 
second hits triggering innate immune responses remain to be 
identified. There is recent evidence for involvement of LPS 
in ALS (Zhang et al., 2009a, 2011) and of endogenous retro-
virus (HEVR-K) expression (Douville et al., 2011). In this 
study, we show that aging is associated with p65 nuclear 
translocation in the spinal cord of TDP-43 transgenic mice 
(Fig. S1 D), but the exact factors underlying this phenome-
non remain to be defined
There is a recent report of mutations in the gene coding 
for vasolin-containing protein (VCP) associated with 1–2% of 
familial ALS cases (Johnson et al., 2010). It is well established 
that VCP is involved in the control of the NF-B pathway 
through regulation of ubiquitin-dependent degradation of 
IB-. For instance, mutant VCP expression in mice resulted 
in increased TDP-43 levels and hyperactivation of NF-B 
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anti–TDP-43 polyclonal (ProteinTech), and anti-HA antibody (clone 3F10; 
Roche). After subsequent washing, the beads were incubated overnight at 
4°C with 400 µg of cell lysate. Antibody-bound complexes were eluted by 
boiling in Laemmli sample buffer. Supernatants were resolved by 10% SDS-
PAGE and transferred on nitrocellulose membrane (Bio-Rad Laboratories). 
The membrane was incubated with anti-p65 antibody, and immunoreactive 
proteins were visualized by chemiluminescence (PerkinElmer) as described 
previously (Dequen et al., 2008). In some cases, phospho-p65Ser536 (Cell Sig-
naling Technology) and phospho-p50337 (Santa Cruz Biotechnology, Inc.) 
were used at a concentration of 1:1,000.
Mass spectrometer analysis. BV-2 microglial cells were transiently trans-
fected with plasmid vector pCMV–TDP-43WT coding for TDP-43WT tagged 
with HA and subsequently treated with LPS. 48 h after transfection, the LPS-
challenged BV-2 cells were then harvested, and cell extracts were coimmuno-
precipitated with anti-HA antibody. Proteins were resolved in 4–20% 
Tris-glycine gels (Precast gels; Bio-Rad Laboratories) and stained with Sypro-
Ruby (Bio-Rad Laboratories). Protein bands from the gel were excised and 
subjected to mass spectrometer analysis at the Proteomics Platform, Quebec 
Genomics Centre. The experiments were performed on a Thermo Surveyor 
MS pump connected to an LTQ linear ion trap mass spectrometer (Thermo 
Fisher Scientific) equipped with a nanoelectrospray ion source (Thermo Fisher 
Scientific). Scaffold (version 1.7; Proteome Software Inc.) was used to validate 
tandem mass spectrometry–based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at >90.0% probabil-
ity as specified by the Peptide Prophet algorithm (Keller et al., 2002).
Immunofluorescence microscopy. Cells were grown to 70% confluence 
on glass coverslips and fixed in 2% paraformaldehyde for 30 min. In some 
cases, BV-2 cells were transiently transfected with the pCMV-TDP-43WT 
and pCMV-p65 vectors using the Lipofectamine 2000 reagent. After fixa-
tion with 4% paraformaldehyde, cells were washed in PBS, and permeabi-
lized with 0.2% Triton X-100 in PBS for 15 min. After blocking coverslips 
with 5% normal goat serum for 1 h at room temperature, primary antibody 
incubations were performed in 1% normal goat serum in PBS overnight, 
followed by an appropriate Alexa Fluor 488 or 594 secondary antibody (In-
vitrogen) for 1 h at room temperature. Similar procedures were used for 
staining spinal cord sections from TDP-43 transgenic mice and sections of 
sporadic ALS cases. Cells were viewed using a 40× or 63× oil immersion 
objective on a DM5000B microscope (Leica).
Quantitative real-time RT-PCR. Real-time RT-PCR was performed 
with a LightCycler 480 (Roche) sequence detection system using Light-
Cycler SYBR green I at the Quebec Genomics Centre. Total RNA was 
extracted from cell culture experiments using TRIZOL reagent (Invitro-
gen). Total RNA was treated with DNase (QIAGEN) to get rid of ge-
nomic DNA contaminations. Total RNA was the quantified using 
Nanodrop, and its purity was verified by Bioanalyzer 2100 (Agilent Tech-
nologies). Gene-specific primers were constructed using the GeneTools 
software (Biotools Inc.). Three genes, Atp5, Hprt1, and GAPDH, were 
used as internal control genes. The primers used for the analysis of genes 
are given in Table S2.
Cytotoxicity assay. N2a cells were transfected with pCMV–hTDP-43 
(both WT and mutants). 48 h after transfection, cells were treated with the 
conditioned media derived from BV-2 cells, some of which were treated 
with LPS (0111:B4 serotype; Sigma-Aldrich). 24 h after challenging N2a 
cells, culture supernatants were assayed for CytoTox-ONE Homogeneous 
Membrane Integrity Assay (Promega), a fluorimetric assay which depends on 
the levels of LDH released as the result of cell death (Swarup et al., 2007a). 
The assay was performed according to the manufacturer’s protocol. Fluores-
cence was measured using a SpectraMAX Gemini EM fluorescence plate 
reader (Molecular Devices) at an excitation wavelength of 560 nm and an 
emission wavelength of 590 nm. Similar techniques were used for primary 
cortical neurons derived from TDP-43 transgenic mice.
and mutant IB- (IBSR), containing Ser32 and Ser36 to alanine muta-
tions, were gifts from the laboratory of M.J. Tremblay (Centre de Recher-
che du Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, 
Canada). To create a human pCMV–TDP-43, the cDNA library from 
human myeloid cells was amplified by PCR using primers as described in 
Table S1. These products were subcloned into TOPO vector (Invitrogen) 
and later digested with Kpn1–BamHI restriction enzymes and subcloned in 
frame into pcDNA3.0 vector to form pCMV–TDP-43WT. The HA tag was 
later added by PCR. HA-tagged TDP-43N, TDP-43RRM-1, TDP-43RRM-2, 
and TDP-43C deletion mutants were constructed by PCR amplification 
and cloned between Kpn1–BamHI sites using the primers described in Table S1. 
Point mutations (pCMV–TDP-43A315T and pCMV–TDP-43G348C) were 
inserted by PCR using site-directed mutagenesis.
Cell culture and transfection. Mouse microglial BV-2 and mouse neuro-
blastoma N2a cells were maintained in DME (Invitrogen) with 10% FBS and 
antibiotics. Cells were transfected using Lipofectamine 2000 transfection re-
agent (Invitrogen) according to the manufacturer’s instructions. At 48 h after 
transfection, the cells were harvested, and the extracts were prepared for 
downstream assays.
Primary cell cultures. Primary microglial culture from brain tissues of neo-
natal (P0-P1) C57BL/6, TDP-43WT, TDP-43A315T, and TDP-43G348C mice 
were prepared as described previously (Weydt et al., 2004). In brief, the brain 
tissues were stripped of their meninges and minced with scissors under a dis-
secting microscope in DME. After trypsinization (0.5% trypsin, 10 min, 
37°C/5% CO2), the tissue was triturated. The cell suspension was washed in 
culture medium for glial cells (DME supplemented with 10% FBS [Invitro-
gen], 1 mM l-glutamine, 1 mM Na pyruvate, 100 U/ml penicillin, and 
100 mg/ml streptomycin) and cultured at 37°C/5% CO2 in 75-cm2 Falcon 
tissue culture flasks (BD) coated with 10 mg/ml poly-d-lysine (PDL; Sigma-
Aldrich) in borate buffer (2.37 g borax and 1.55 g boric acid dissolved in 500 ml 
of sterile water, pH 8.4) for 1 h and then rinsed thoroughly with sterile, glass-
distilled water. Half of the medium was changed after 6 h in culture and every 
second day thereafter, starting on day 2, for a total culture time of 10–14 d. 
Microglia were shaken off the primary mixed brain glial cell cultures 
(150 rpm, 37°C, 6 h) with maximum yields between days 12 and 16, seeded 
(105 cells per milliliter) onto PDL-pretreated 24-well plates (1 ml per well), and 
grown in culture medium for microglia (DME supplemented with 10% FBS, 
1 mM l-glutamine, 1 mM Na pyruvate, 50 mM 2-mercaptoethanol, 100 U/ml 
penicillin, and 100 mg/ml streptomycin). The cells were allowed to adhere 
to the surface of a PDL-coated culture flask (30 min, 37°C/5% CO2). After 
removal of primary microglial culture, the remaining cells were mainly astro-
cytes. Purity of the astrocytes was >90%. Astrocytes were maintained in a me-
dium consisting of DME supplemented with 10% FBS, 1 mM l-glutamine, 
1 mM Na pyruvate, 50 mM 2-mercaptoethanol, 100 U/ml penicillin, and 
100 mg/ml streptomycin. Primary cortical cultures from brain tissues of gesta-
tion day 16 (E16) C57BL/6, TDP-43WT, TDP-43A315T, and TDP-43G348C 
mice were prepared as described previously (Hilgenberg and Smith, 2007). In 
brief, dissociated cortical cells (2.5–3.5 hemispheres) were plated onto PDL-
coated 24-well plates, containing DME supplemented with 20 mM glucose, 
2 mM glutamine, 5% FBS, and 5% horse serum. Cytosine arabinoside was 
added 4–5 d after the plating to halt the growth of nonneuronal cells. Cultures 
were maintained at 37°C in a humidified CO2 incubator and used for experi-
ments between 14 and 21 d in vitro. Cells were treated with WA at a final 
concentration of 1 µM for 24 h. BMMs were isolated and cultured using es-
tablished protocols as described previously (Davies and Gordon, 2005).
Coimmunoprecipitation and Western blot assays. After transfection of 
plasmids, BV-2 cells were cultured for 48 h and then harvested with lysis 
buffer (25 mM Hepes-NaOH, pH 7.9, 150 mM NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 0.5% Triton X-100, 1 mM dithiothreitol, and protease inhi-
bitor cocktail). Alternatively, spinal cords from TDP-43 transgenic mice or 
sporadic ALS subjects along with controls were lysed in the buffer. The ly-
sate was incubated with 50 µl Dynabeads (protein G beads; Invitrogen), 
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200 Imaging System (Caliper Life Sciences). 25 min before imaging session, 
the mice received intraperitoneal injection of the luciferase substrate 
d-luciferine (150 mg/kg for mice between 20 and 25 g, 150–187.5 ml of a 
solution of 20 mg/ml of d-luciferine dissolved in 0.9% saline was injected; 
Caliper Life Sciences).
Statistical analysis. For statistical analysis, the data obtained from indepen-
dent experiments are presented as the mean ± SEM; they were analyzed 
using a paired Student’s t test with Mann-Whitney test, one-way analysis of 
variance (ANOVA) with Kruskal-Wallis test, or two-way ANOVA with 
Bonferroni adjustment for multiple comparisons using Prism software ver-
sion 5.0 (GraphPad Software). For rotarod and GFAP imaging experiments, 
repeated measures ANOVA was used. In some experiments, an unpaired 
Student’s t test followed by a Welch’s test was performed. Differences were 
considered significant at P < 0.05.
Online supplemental material. Fig. S1 demonstrates reverse immuno-
precipitation of TDP-43 with p65 antibody and EMSA supershift assay and 
describes how p65 activation is age dependent in TDP-43WT transgenic 
mice. Table S1 lists the primers used for TDP-43 cloning. Table S2 lists the 
primers used for quantitative RT-PCR. Table S3 gives details of patients 
examined during the study. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20111313/DC1.
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a Bradford assay (Bio-Rad Laboratories). Interaction between p65 in the 
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EMSA was then performed using the NF-B EMSA kit. For supershift as-
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buffer (Promega), and an ensuing 1-min centrifugation step (20,000 g) 
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supernatant were tested for luciferase activity (luciferase assay kit; Promega) 
and for -galactosidase activity (-galactosidase assay kit; Promega) to adjust 
for transfection efficiency.
RNA interference. To selectively prevent TDP-43 expression, we used the 
RNA interference technology. A double-stranded RNA (siRNA) was used to 
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et al., 2007a). The siRNAs directed against the murine TDP-43 mRNA (Gen-
Bank accession no. NM_145556.4) consisted of sequences with symmetrical 
3-UU overhangs using siRNA Target Finder (Invitrogen). The sequence of the 
most effective TDP-43 siRNAs represented is as follows: 5-AGGAAUCAGC-
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